Camp4 Therapeutics Corp 8K

CAMP4 Therapeutics announced Q2 2026 results alongside regulatory progress for its CMP-002 clinical program and completion of a $50.1 million private placement tranche extending cash runway through 2028.

On August 13, 2026, CAMP4 Therapeutics Corporation reported its financial results for the quarter ended June 30, 2026 and highlighted key corporate developments, including obtaining regulatory clearances in Australia and Argentina to initiate its first‑in‑human Phase 1/2 clinical trial of lead candidate CMP-002 for SYNGAP1-related disorder with trial launch expected in Q4 2026, submitting additional regulatory filings in the EU and UK to broaden trial enrollment, closing a fully subscribed second tranche of its previously announced private placement that raised $50.1 million and extended the company’s cash runway through the end of 2028, relocating its corporate headquarters to Watertown, Massachusetts, and disclosing that its higher quarterly net loss was primarily driven by a $20.9 million non‑cash loss related to a change in fair value of a derivative tranche liability from the September 2025 financing.

Filing Facts

CIK

1736730

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-056758

Alert Tier

6